Charles Decuir: Cancer immunotherapies for all patients - https://www.miragenews.com/c...

2 years ago

Charles Decuir: CABYR-a/b and CABYR-c hold promise as targets for specific immunotherapy - https://medicalxpress.com/n...

2 years ago

Charles Decuir: Oncology Pharma, Inc. Is Pursuing the Development of Its Small Molecule Drug for the Treatment of Colon Cancer - https://www.biospace.com/a...

2 years ago

Charles Decuir: Dr. Hubbard on Utilizing Single-Agent Immunotherapy in MSI-H CRC - https://www.onclive.com/v...

2 years ago

Charles Decuir: Immunotherapy Combination Aims To Improve Success of Cancer Treatment - https://www.technologynetwor...

2 years ago

Charles Decuir: Dana-Farber Cancer Institute Announces $2 Billion Fundraising Campaign to Defy Cancer - https://www.businesswire.com/n...

2 years ago

Charles Decuir: Bristol Myers writes $200M check for rights to Agenus checkpoint inhibitor https://medcitynews.com/2...

2 years ago

Charles Decuir: New England Cancer Specialists Adopt Deep Lens’ Clinical Trial Matching Solution VIPER™ to Expand Clinical Trial Offeringhttps://www.valdostadailytim...

2 years ago